Claims
- 1. A nucleic acid comprising the nucleotide sequence of the genome of a non-subtype B HIV-1 virus, wherein said nucleotide sequence is selected from sequences having SEQ ID NOS: 1 to 11 or a complementary sequence thereof.
- 2. The nucleic acid of claim 1, wherein said nucleic acid comprises a nucleotide sequence of at least 12 contiguous bases of said nucleic acid or a complementary sequence thereof.
- 3. The nucleic acid of claim 1, wherein said nucleic acid comprises a nucleotide sequence of a LTR of said nucleic acid or a complementary sequence thereof.
- 4. The nucleic acid of claim 1, wherein said nucleic acid encodes a polypeptide selected from the group consisting of Gag, Pol, Vif, Vpr, Env, Tat, Rev, Nef and Vpu, wherein the nucleic acid is from the genome of a non-subtype B HIV-1 virus selected from the group consisting of 92RW009.6, 92NG003.1, 92NG083.2, 93BR020.1, 93BR029.4, 90CF056.1, 94CY032.3, 94CY017.41, 96ZM651.8, 96ZM751.3, and 94IN476.104 or a complementary sequence thereof.
- 5. A vector comprising a nucleic acid of claim 1.
- 6. A cell comprising a nucleic acid of claim 1.
- 7. A cell comprising the vector of claim 5.
- 8. A polypeptide encoded by a nucleic acid of claim 1.
- 9. The polypeptide of claim 8 comprising a contiguous sequence of at least 13 amino acids.
- 10. A method for producing a polypeptide of claim 8, comprising the step of growing a cell under conditions such that the encoded polypeptide is produced, said cell comprising the nucleic acid of the polypeptide of claim 8.
- 11. A method for producing a polypeptide of claim 8, comprising the step of growing a cell under conditions such that the encoded polypeptide is produced, said cell comprising a vector having the nucleic acid of the polypeptide of claim 8.
- 12. A method of inducing serum antibodies that bind at least one polypeptide of claim 8, comprising the step of administering to a mammal, in a physiologically acceptable carrier, an amount of polypeptide of claim 8 sufficient to elicit production of said antibodies.
- 13. A method for detecting the presence of antibodies to a non-subtype B HIV-1 virus in a sample comprising the step of contacting said sample with said polypeptide of claim 8 under conditions that allow the formation of an antibody-antigen complex and detecting the complex.
- 14. An antibody to a non-subtype B HIV-1 virus, said antibody binding at least one polypeptide of claim 8, wherein said antibody is made by administering to a mammal an amount of said polypeptide in a physiological carrier sufficient to elicit production of said antibody.
- 15. A composition comprising the antibody of claim 14, and a physiologically acceptable carrier.
- 16. A method for detecting the presence of a non-subtype B HIV-1 virus in a sample comprising the step of contacting said sample with the antibody of claim 14 under conditions that allow the formation of an antibody-antigen complex and detecting said complex.
- 17. A kit for detecting the presence of a non-subtype B HIV-1 virus in a sample comprising the antibody of claim 14.
- 18. A method of inducing serum antibodies that bind at least one polypeptide of claim 8, comprising the step of administering to a mammal, in a physiologically acceptable carrier, the nucleic acid which encodes said polypeptide(s) and which produces an immunologically sufficient amount of the encoded polypeptide to elicit said antibodies.
- 19. An antibody to a non-subtype B HIV-1 virus, said antibody binding at least one polypeptide of claim 8, wherein said antibody is made by administering to a mammal the nucleic acid encoding said polypeptide(s) in a physiologically acceptable carrier, wherein said nucleic acid produces an immunologically sufficient amount of the encoded polypeptide(s) to elicit said antibody.
- 20. A composition comprising the antibody of claim 19, and a physiologically acceptable carrier.
- 21. A method for detecting the presence of a non-subtype B HIV-1 virus in a sample comprising the step of contacting said sample with an antibody of claim 19 under conditions that allow the formation of an antibody-antigen complex and detecting said complex.
- 22. A kit for detecting the presence of a non-subtype B HIV-1 virus in a sample comprising the antibody of claim 19.
- 23. A method for detecting the presence of a non-subtype B HIV-1 virus in a sample comprising the steps of:
contacting said sample with a nucleic of claim 1; and detecting said nucleic acid bound to the genomic DNA, mRNA or cDNA of the non-subtype B HIV-1 virus.
- 24. A nucleic acid probe comprising a sequence of at least 19 contiguous nucleotides of a nucleic acid of claim 1.
- 25. A method of detecting the presence of a non-subtype B HIV-1 virus in a biological sample comprising the steps of:
contacting the nucleic acid of the biological sample with the nucleic acid probe of claim 24; and detecting the presence or absence of complexes formed between said nucleic acid of the biological sample and said nucleic acid probe.
- 26. A method of detecting the presence of a non-subtype B HIV-1 virus in a biological sample comprising the steps of:
contacting said biological sample with at least two nucleic acid probes of claim 26;amplifying the RNA of the biological sample via reverse transcription-polymerase chain reaction to produce amplification products; and detecting the presence or absence of amplification products.
- 27. A composition comprising the nucleic acid probe of claim 24.
- 28. A method for analyzing a first nucleotide sequence comprising comparing the nucleotide sequence of any one of the nucleotide sequences having SEQ ID NOS: 1 to 11 with said first sequence.
- 29. A method for analyzing a first amino acid sequence comprising comparing the amino acid sequence of any one of the amino acid sequences set forth in FIGS. 14-22 with said first sequence.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a divisional application of non-provisional U.S. Ser. No. 09/184,418, filed Nov. 2, 1998.
FEDERAL FUNDING LEGEND
[0002] This work was funded by grants RO1 AI25291; and NO1 AI35170 from the National Institutes of Health. Therefore, the government may have certain rights in the invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09184418 |
Nov 1998 |
US |
Child |
10290579 |
Nov 2002 |
US |